Most Recent
A judge has rejected applications by the AFL and the Geelong Football Club to declass a concussion class action, but has ordered an initial trial that will cover only a fraction of the 38-year claim period in the case.
A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
Construction PRO
Sydney developer Tiptell has won its bid to exit a combustible cladding class action against 3A Composites and Halifax to bring its own claim for $15 million.
The developer of a tower in Mascot which is said to contain combustible cladding can opt out of a class action against 3A Composites and Halifax to bring its own claim for $15 million.
Brittany Higgins must cover 80 per cent of Linda Reynolds' legal costs on top of $315,000 in damages the former senator was awarded in her defamation case over social media posts that implied she mishandling Higgins' rape allegations against Bruce Lehrmann.
A judge has signed off on a $13.5 million penalty agreed to by retailer The Good Guys for making misleading statements about store credit and StoreCash schemes to customers.
A judge has rejected all but two claims by ASIC in a suit against car finance provider Money3 and criticised how the regulator ran its case, saying it had consumed an "inordinate and disproportionate amount of the judicial and administrative resources of the court".
The peak body for community legal centres has lost its bid to declass a class action alleging survivors of institutional child sexual abuse who settled their claims under the National Redress Scheme were given negligent ‘cookie cutter’ legal advice.
A shareholder class action over BHP’s disclosures about a Brazilian dam that collapsed 10 years ago has settled for $110 million on the eve of trial, one of a handful of class actions to settle for over $100 million.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.